Aviva
ALLO icon

Aviva’s Allogene Therapeutics ALLO Stock Holding History

Aviva’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-35,003
Closed -$883K – 941
2020
Q4 		$883K Sell
35,003
-28,380
-45% -$925K ﹤0.01% 868
2020
Q3 		$2.39M Buy
63,383
+8,823
+16% +$333K 0.01% 626
2020
Q2 		$2.34M Sell
54,560
-127,530
-70% -$4.61M 0.01% 630
2020
Q1 		$3.54M Buy
182,090
+113,180
+164% +$2.7M 0.03% 603
2019
Q4 		$1.79M Buy
+68,910
New +$1.9M 0.01% 827

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Aviva's ALLO Position: Q1 2021 in Review

Aviva sold out of Allogene Therapeutics (ALLO) in Q1 2021, closing a stake of 35,003 shares — an estimated $883K sold.

Aviva first reported a position in ALLO in Q4 2019 and held it in 5 quarters. The position peaked at $3.54M in Q1 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q1 2021.

  • Aviva reported no remaining Allogene Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Aviva sold 35,003 Allogene Therapeutics shares in Q1 2021, an estimated $883K.
  • Aviva first reported a position in Allogene Therapeutics in Q4 2019 and held it in 5 quarters.
  • Aviva's Allogene Therapeutics position peaked at $3.54M in Q1 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2021.

Based on Aviva's 13F filing for Q1 2021, filed 13 May 2021.